Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

UNCOVERED: Achv - The Untold Story

Achieve Life Sciences Stock Has Nearly Tripled in the Last Year. Now It Just Needs to Turn a Profit.

Achieve Life Sciences (ACHV) is a $685 million biotech focused on cytisinicline-based nicotine addiction treatments, showing strong recent technical momentum. ACHV has surged 173% over 52 weeks. Shares recently hit a 3-year high earlier in July. Despite robust technicals, ACHV remains highly speculative, as it has not yet begun monetizing...

Achieve Life Sciences Q1 Earnings Call Highlights

Achieve Life Sciences (NASDAQ:ACHV) used its first-quarter 2026 earnings call to outline a transition period marked by new leadership, a major financing, manufacturing changes tied to its cytisinicline regulatory timeline and preparations for a potential commercial launch in 2027. Dr. Andrew Goldbe

FDA Unveils First Experimental Drugs Under Fast-Track Voucher Plan To Cut Drug Review Times

FDA Unveils First Experimental Drugs Under Fast-Track Voucher Plan To Cut Drug Review Times

The Food and Drug Administration announced on Thursday the first round of experimental drugs to be included in a priority voucher program. This FDA initiative is designed to expedite drug review processes for products that align with critical U.S. national health priorities, reducing review times from 10 to 12 months…

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Achieve Life Sciences Inches Closer To FDA Nod For First New Quit-Smoking Drug In 20 Years

Achieve Life Sciences Inc. (NASDAQ:ACHV) is moving closer to a pivotal moment as it seeks FDA approval for cytisinicline, a potential first new smoking cessation therapy in nearly two decades, positioning the company for a high-stakes commercial launch in 2026.

ACHV: First Quarter 2022 Results

By John Vandermosten, CFA NASDAQ:ACHV READ THE FULL ACHV RESEARCH REPORT

Achieve Life Sciences: Q1 Earnings Insights

Achieve Life Sciences (NASDAQ:ACHV) reported its Q1 earnings results on Thursday, May 12, 2022 at 04:00 PM. Here's what investors need to know about the announcement.

ACHV: Topline Data from ORCA-2 Smoking Cessation Trial

By John Vandermosten, CFA NASDAQ:ACHV READ THE FULL ACHV RESEARCH REPORT

inkl

Read news from The Economist, FT, and more,
with one subscription

Achieve Life Sciences Aces Pivotal Cytisinicline Study In Smoking Cessation

Achieve Life Sciences Aces Pivotal Cytisinicline Study In Smoking Cessation

Achieve Life Sciences Inc (NASDAQ:ACHV) has announced positive topline results from the Phase 3 ORCA-2 trial of 3mg cytisinicline for 6-weeks or 12-weeks compared to a placebo in 810 adult smokers. The 6- and 12-week cytisinicline treatments demonstrated significantly better quit rates than placebo, with odds ratios of 8.0 and 6.3, respectively. Subjects…

ACHV: 2021 Results: ORCA-3 Underway, ORCA-V1 Soon to Start

By John Vandermosten, CFA NASDAQ:ACHV READ THE FULL ACHV RESEARCH REPORT

Achieve Life Sciences: Q4 Earnings Insights

Achieve Life Sciences: Q4 Earnings Insights

Achieve Life Sciences (NASDAQ:ACHV) reported its Q4 earnings results on Thursday, March 10, 2022 at 08:00 AM. Here's what investors need to know about the announcement.

ACHV: The Final Phase III Begins

By John Vandermosten, CFA NASDAQ:ACHV READ THE FULL ACHV RESEARCH REPORT

Achieve Life Sciences Initiates Pivotal Trial Of Cytisinicline For Smoking Cessation

Achieve Life Sciences Initiates Pivotal Trial Of Cytisinicline For Smoking Cessation

Achieve Life Sciences Inc (NASDAQ: ACHV) has

1

People

John Vandermosten

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

Silicon Valley Bank

Food and Drug Administration

Achieve Life Sciences

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

415,768 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play